Table 2.

Response to neoadjuvant chemotherapy, CRT, and complete response rate by FcγRIIa and FcγRIIIa polymorphisms and treatment

Response rate after neoadjuvant chemotherapy (%)Treatment by FcγR SNP interactionResponse rate after CRT (%)Treatment by FcγR SNP interactionComplete response rate (%)Treatment by FcγR SNP interaction
FcγR polymorphismCAPOX (n = 54)CAPOX-C (n = 51)PCAPOX (n = 54)CAPOX-C (n = 51)PCAPOX (n = 54)CAPOX-C (n = 51)P
HH63.663.60.73575.080.00.9447.118.20.434
HR50.065.272.082.614.812.0
RR41.764.383.385.77.726.7
HH63.663.60.47575.783.80.85412.517.50.645
HR/RR47.464.975.080.07.118.2
VV33.31000.54650.01000.976020.00.808
VF59.156.572.778.38.316.7
FF47.668.285.786.418.218.2
VV33.31000.99950.01000.999020.00.999
VF/FF53.562.279.182.213.017.4
HH and/or VV57.166.70.81573.381.80.9575.914.30.686
R and F48.663.976.583.313.518.9